Immunologically mediated regression of a murine lymphoma after treatment with anti-L3T4 antibody. A consequence of removing L3T4+ suppressor T cells from a host generating predominantly Lyt-2+ T cell-mediated immunity (Q36355782)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Immunologically mediated regression of a murine lymphoma after treatment with anti-L3T4 antibody. A consequence of removing L3T4+ suppressor T cells from a host generating predominantly Lyt-2+ T cell-mediated immunity	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

13 August 2017

Immunologically mediated regression of a murine lymphoma after treatment with anti-L3T4 antibody. A consequence of removing L3T4+ suppressor T cells from a host generating predominantly Lyt-2+ T cell-mediated immunity (English)

1 reference

Europe PubMed Central

13 August 2017

author name string

M Awwad

1

1 reference

Europe PubMed Central

13 August 2017

R J North

2

1 reference

Europe PubMed Central

13 August 2017

language of work or name

0 references

publication date

1 December 1988

1 reference

Europe PubMed Central

13 August 2017

Journal of Experimental Medicine

1 reference

Europe PubMed Central

13 August 2017

168

1 reference

Europe PubMed Central

13 August 2017

6

1 reference

Europe PubMed Central

13 August 2017

2193-2206

1 reference

Europe PubMed Central

13 August 2017

Mechanisms of anti-tumor action of Corynebacterium parvum. I. Potentiated tumor-specific immunity and its therapeutic limitations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2189164

30 September 2017

Concomitant Tumor Immunity and the Resistance to a Second Tumor Challenge

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2189164

30 September 2017

Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2189164

30 September 2017

Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2189164

30 September 2017

Down-regulation of the antitumor immune response.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2189164

30 September 2017

Ly 1+2- suppressor T cells down-regulate the generation of Ly 1-2+ effector T cells during progressive growth of the P815 mastocytoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2189164

30 September 2017

Immunologic regulation of experimental cutaneous leishmaniasis. V. Characterization of effector and specific suppressor T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2189164

29 June 2018

Cellular and humoral immunity to Leishmania major in genetically susceptible mice after in vivo depletion of L3T4+ T cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2189164

29 June 2018

Importance of Lyt 1+ T-cells in the antitumor activity of an immunomodulator, SSM, extracted from human-type Tubercle bacilli.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2189164

29 June 2018

Cyclophosphamide (Cy)-facilitated adoptive immunotherapy of a Cy-resistant tumour. Evidence that Cy permits the expression of adoptive T-cell mediated immunity by removing suppressor T cells rather than by reducing tumour burden.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2189164

29 June 2018

Regulation of cellular and humoral immune responses to collagen type I or collagen type II.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2189164

29 June 2018

Immunotherapy of the nonobese diabetic mouse: treatment with an antibody to T-helper lymphocytes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2189164

29 June 2018

Models of adoptive T-cell-mediated regression of established tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2189164

22 September 2018

Adoptive immunization against an established tumor with cytolytic versus memory T cells. Immediate versus delayed onset of regression.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2189164

22 September 2018

Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/2974065

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic effect of anti-L3T4 monoclonal antibody GK1.5 on cutaneous leishmaniasis in genetically-susceptible BALB/c mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/2974065

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The Lyt phenotype of the T cells responsible for in vivo tumor rejection in syngeneic mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/2974065

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Frequency analysis of augmented CTL production associated with Corynebacterium parvum-induced tumour regression

1 reference

https://pubmed.ncbi.nlm.nih.gov/2974065

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Subtherapeutic numbers of tumour-sensitized, L3T4+, Ly 1+2- T cells are needed for endotoxin to cause regression of an established immunogenic tumour

1 reference

https://pubmed.ncbi.nlm.nih.gov/2974065

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Islet allograft survival after a single course of treatment of recipient with antibody to L3T4

1 reference

https://pubmed.ncbi.nlm.nih.gov/2974065

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of anti-L3T4 monoclonal antibody treatment on first-set rejection of murine cardiac allografts

1 reference

https://pubmed.ncbi.nlm.nih.gov/2974065

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sublethal, whole-body ionizing irradiation can be tumor promotive or tumor destructive depending on the stage of development of underlying antitumor immunity

1 reference

https://pubmed.ncbi.nlm.nih.gov/2974065

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1084/JEM.168.6.2193

1 reference

Europe PubMed Central

13 August 2017

1 reference

Europe PubMed Central

13 August 2017

1 reference

Europe PubMed Central

13 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36355782&oldid=1519218327"